Introduction {#sec1}
============

Sarcoidosis is a multisystem granulomatous disease characterized by noncaseating granulomas predominantly infiltrating the lungs, lymph nodes and skin \[[@cit0001]\].

This disease predominantly affects individuals between the age of 20 and 60, with an incidence ranging from 5--40 cases per 100,000 people in a white population up to 3--4 times higher in African Americans, with the lowest incidence recorded in Japan \[[@cit0002], [@cit0003]\]. A significant proportion of patients suffering from sarcoidosis resolve spontaneously, resulting in a relatively low mortality rate, ranging from 1% to 5% depending on the severity of disease, location, age, ethnicity, and gender \[[@cit0004]\]. Nevertheless, a small number of patients develop a chronic or progressive disease with a fatal outcome, mainly due to respiratory or cardiac involvement \[[@cit0004]\]. The cause of sarcoidosis remains unknown, but considering that the affected organs represent entry points for immunologically active factors, it is believed that disease development requires exposure to environmental antigens, which acts as a trigger in a susceptible host.

Sarcoidosis is more common and occurs in a more serious form in darkly pigmented individuals living in regions with a higher incidence of vitamin D deficiency, such as the African-American population in the Southern United States of America \[[@cit0005]--[@cit0007]\]. This relationship was first brought to the attention of the scientific community more than 70 years ago, when hypercalcemia, which would worsen in patients consuming a vitamin D rich diet, was underlined as a feature of sarcoidosis, and the relation between vitamin D and calcium abnormalities was hypothesized \[[@cit0008]\]. Two decades later, a group of authors proposed that the hormone causing this form of vitamin D intoxication is produced at an extra renal site, and another 30 years later calcitriol (1,25(OH)2D), produced by macrophages, was identified as the cause of hypercalcemia \[[@cit0009], [@cit0010]\].

Hypovitaminosis D has been identified as a risk factor for the development of active tuberculosis, and may also play a role in the pathogenesis of sarcoidosis.

Several studies report symptomatic osteomalacia with bone pain, as well as the sensation of fatigue and exhaustion, in sarcoidosis patients \[[@cit0007], [@cit0011], [@cit0012]\]. Most of these patients have had normal serum levels of calcitriol with low levels of inactive vitamin 25(OH)D \[[@cit0013], [@cit0014]\]. Sarcoid granulomas represent sites of autonomous conversion of vitamin 25(OH)D to vitamin 1,25(OH)~2~D, and the level of calcitriol, which downregulates dendritic cells blocking the immune response, has been positively associated with the disease activity \[[@cit0015], [@cit0016]\]. Another proposed step in the pathogenesis of sarcoidosis linked to vitamin D is the formation of noncaseating granulomas instead of caseating granulomas formed in tuberculosis, as a result of a defect in innate immunity \[[@cit0017]\].

The interplay of a relevant exposure, vitamin D deficiency and a susceptible host in the development of sarcoidosis has underlined a role of genetic polymorphisms in the pathogenesis of this disease \[[@cit0001]\]. It is believed that sarcoidosis, in its complexity, is influenced by numerous genes involved in vitamin D metabolic and signaling pathways. Among them, proteins encoded by *CYP2R1*, *DBP*, *CYP27B1*, and *VDR* genes play a significant role in metabolism of vitamin D and conversion from the inactive to its active form. The *CYP2R1* gene, together with *CYP3A4* and *CYP27A1* genes, encodes the 25-hydroxylating cytochrome P450 enzymes; vitamin D binding protein gene (*DBP*) encodes the principle vitamin D transport protein; *CYP27B1* encodes the cytochrome P450 enzyme which 1α-hydroxylates 25(OH)D to form 1,25(OH)~2~D. Finally, the *VDR* gene encodes the vitamin D receptor which binds 1,25(OH)~2~D and forms a heterodimer with the retinoid X receptor to mediate the biological actions of vitamin D \[[@cit0018]\].

The aim of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in *CYP2R1* (rs10741657), *CYP27B1* (rs10877012*)*, *DBP* (rs7041; rs4588), and *VDR* (rs2228570) genes and sarcoidosis, as well as the association between these SNPs and 25(OH)D levels in sarcoidosis patients.

Material and methods {#sec2}
====================

We conducted a case-control study which included 86 patients with a diagnosis of sarcoidosis (cases) and 50 healthy subjects (controls). All patients were recruited from January 2015 until December 2016 at the University Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Belgrade. On the day when blood samples for vitamin 25(OH)D analyses and genotyping were obtained, a detailed history of the disease course and duration were recorded.

All patients participating in this study were informed about the study requirements and aims, and signed the informed consent form. The study was approved by the Ethics Committee of the Clinical Center of Serbia, Belgrade, and the research was carried out in compliance with the Helsinki Declaration.

Patients and controls {#sec2.1}
---------------------

For sarcoidosis patients, the inclusion criteria were a diagnosis of sarcoidosis confirmed by a detailed history of signs and symptoms, a chest X-ray, lung function tests, and a biopsy. All cases were suffering from sarcoidosis, defined as the form of the disease with both symptoms and signs of sarcoidosis activity and parameters of the activity present for more than 2 years. Controls were healthy subjects who agreed to participate in this study and for their collaboration received a detailed report on their blood analyses. Exclusion criteria for cases and controls were the same and included any history of diabetes mellitus, ischemic heart disease, chronic renal failure, jaundice or seropositivity for hepatitis B surface antigen, hepatitis C virus or human immunodeficiency virus.

Five ml of blood was drawn from the median cubital vein from cases and controls. Two ml were transferred into vials containing EDTA and frozen at --20°C for subsequent DNA extraction, and 3 ml were added to serum vials and sent to the laboratory within 2 h of collection, where serum was isolated from clotted blood by centrifugation and stored at --20°C for subsequent determination of 25(OH)D concentration.

Serum 25(OH)D analysis {#sec2.2}
----------------------

The adequacy of vitamin D intake is commonly evaluated by measuring the levels of vitamin 25(OH)D, which is the major circulating form of vitamin D and is considered the best available clinical indicator of vitamin D status \[[@cit0019], [@cit0020]\]. Although 1,25(OH)2D (calcitriol) is the active metabolite, only a tiny fraction of the 25(OH)D is converted to it, and it does not reflect the body stores of vitamin D. In addition, it has a much shorter half-life than 25(OH)D, and normal or elevated levels of this metabolite are present even in patients with a vitamin D deficiency \[[@cit0021], [@cit0022]\].

Vitamin D \[25(OH)D\] was measured at the Biochemical Laboratory of the Clinical Center of Serbia, Belgrade using the Elecsys Vitamin D total test. The test is based on the electro-chemo-luminescence method (ECLIA). The commercial reagents used were produced by Roche Diagnostics-Elecsys Vita min D total (REF 05894913190), Roche Diagnostics GmbH, Mannheim, Germany.

Following the reference values, serum vitamin 25(OH)D levels were defined as:

a.  severe deficiency: a serum level of vitamin 25(OH)D \< 10 mg/l;

b.  insufficiency: a serum level of vitamin 25(OH)D 10--30 mg/l;

c.  sufficient: a serum level of vitamin 25(OH)D \> 30 mg/l;

d.  toxicity: a serum level of vitamin 25(OH)D \> 100 mg/l.

Genotyping {#sec2.3}
----------

Genetic analysis was performed in the Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia. Genomic DNA was isolated from whole peripheral blood with the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany), and stored at --20°C until analysis. The detection of gene variants of *CYP2R1*, *CYP27B1*, *DBP* and *VDR* genes was performed using the PCR-RFLP method. Primer sequences and PCR-RFLP conditions are given in Supporting information ([Table I](#t0001){ref-type="table"}).

###### 

Sequences used for genotyping of *CYP2R1*, *CYP27B1*, *DBP* and *VDR* genes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable             Forward                      Reverse                      Annealing temperature \[°C\]   PCR product size \[bp\]   Restriction enzyme
  -------------------- ---------------------------- ---------------------------- ------------------------------ ------------------------- --------------------
  CYP2R1 rs10741657    GGGAAGAGCAATGACATGGA         GCCCTGGAAGACTCATTTTG         56                             287                       *Mnl*I

  CYP27B1 rs10877012   GTGTTCCCTAAGTGTTGTCTC        GCTGACTCGGTCTCCTCTG          56                             666                       *Tfi*I

  DBP rs7041; rs4588   AAATAATGAGCAAATGAAAGAAGAC    CAATAACAGCAAAGAAATGAGTAGA    57                             483                       rs7041/ *Hae*III\
                                                                                                                                          rs4588/ *Sty*I

  VDR rs2228570        AGCTGGCCCTGGCACTGACTCTGGCT   ATGGAAACACCTGCTTCTTCTCCCTC   57                             266                       *Fok*I
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Validation of PCR-RFLP method was conducted using direct sequencing method, for randomly selected samples.

Sample size and statistical analysis {#sec2.4}
------------------------------------

Continuous variables are presented as means with standard deviations or median with 25 and 75 percentiles, depending on the normality of their distribution, while categorical variables are presented as the number and percentage of cases. For continuous variables the distribution was tested using mathematical and graphical methods. Hardy-Weinberg equilibrium (HWE) was tested both for sarcoidosis patients and the control group.

The association between host genotype and sarcoidosis was assessed by univariate logistic regression, with adjustment for age. Results are expressed as odds ratios (OR) with 95% confidence intervals (CI). The dominant model implies comparisons of homozygous genotypes for the major allele versus the group homozygous for the minor allele plus heterozygous genotype. The recessive model implies comparisons of recessive genotypes against heterozygous plus dominant homozygous. Associations between studied genes and 25(OH)D levels were assessed by the χ^2^ (categories of vitamin D: \< 10; 10--30; \> 30 mg/l) test and Mann-Whitney test (continuous values of vitamin D). All tests were two-tailed. The level of significance was set at 0.05. Statistical analysis was performed using the IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.

Results {#sec3}
=======

General characteristics of subjects who participated in the study {#sec3.1}
-----------------------------------------------------------------

Our study included a total of 136 subjects, of whom 86 were patients suffering from sarcoidosis (cases), and 50 were healthy controls. Sarcoidosis patients had a mean age of 48.7 ±10.2 years, ranging from 27 up to 66 years, while the mean age in the control group was 39.2 ±11.3 (ranging from 15--83), and this difference was statistically significant (*p* \< 0.001). The sarcoidosis group consisted of 22 (25.6%) men and 64 (74.4%) women, compared to the control group which consisted of 19 (38%) men and 31 (62%) women. This difference was not statistically significant (*p* = 0.128). The average duration of the disease was 5.9 ±5.2 years, with a median of 4 (range: 2--9 years). Twenty-seven (31.4%) patients suffered from the acute form of sarcoidosis, while the chronic form was evident in 59 (68.6%) patients. Demographic and clinical characteristics of sarcoidosis patients and healthy individuals who participated in this study are shown in [Table II](#t0002){ref-type="table"}.

###### 

Demographic, clinical and serological characteristics of sarcoidosis patients and healthy controls

  Parameter                    Sarcoidosis patients   Healthy individuals   
  ---------------------------- ---------------------- --------------------- ------------
  Demographic data:                                                         
   Number                                             86                    50
   Age                         Mean ± SD              48.7 ±10.2            39.2 ±11.3
   Sex distribution            Women                  64 (74.4%)            31 (62.0%)
  Men                          22 (25.6%)             19 (38.0%)            
  Clinical parameters:                                                      
   Disease activity\*\*\*      Acute                  27 (31.4%)            
  Chronic                      59 (68.6%)                                   
   Organ involved              Lung                   84 (97.7%)            
  CNS                          14 (16.3%)                                   
  Skin                         4 (4.7%)                                     
  Eye                          8 (9.3%)                                     
  Liver                        1 (1.2%)                                     
  Spleen                       3 (3.5%)                                     
  Lymph node                   7 (8.1%)                                     
  Bone                         2 (2.3%)                                     
  Stomach                      1 (1.2%)                                     
  Parotid gland                1 (1.2%)                                     
  Bone marrow                  1 (1.2%)                                     
   Ro stage                    0                      24 (27.9%)            
  1                            30 (34.9%)                                   
  2                            28 (32.6%)                                   
  3                            4 (4.7%)                                     
   Vitamin D status \[mg/l\]   \< 10                  38 (44%)              
  10--30                       43 (50%)                                     
  \> 30                        5 (5.8%)                                     
   Therapy                     Prednisone             57 (66.3%)            
  Methotrexate                 4 (4.7%)                                     
  Prednisone + methotrexate    2 (2.3%)                                     
  Without therapy              23 (26.7%)                                   

Genotypes and sarcoidosis {#sec3.2}
-------------------------

All genotype distributions were in Hardy-Weinberg equilibrium for all studied polymorphisms.

In order to analyze the association between certain genotypes and the risk of sarcoidosis, we used dominant and recessive genetic models. Genotype CC (compared to CA + AA) of *CYP27B1* rs10877012 was more frequent in the control group than in sarcoidosis patients, and this difference was statistically significant ([Figure 1](#f0001){ref-type="fig"}). Persons carrying this genotype had almost 10 times lower odds of suffering from sarcoidosis (OR = 0.116, 95% CI: 0.034--0.394, *p* = 0.001) ([Table III](#t0003){ref-type="table"}). This result shows that the CC genotype is a significant protector against sarcoidosis. In addition, genotype AA (compared to CA + CC) of the *DBP* rs4588 gene was shown to be a significant predictor, increasing the odds of suffering from sarcoidosis eight times (OR = 8.856, 95% CI: 1.006--77.953, *p* = 0.049) ([Table III](#t0003){ref-type="table"}, [Figure 2](#f0002){ref-type="fig"}).

###### 

Genotype distributions and summarized results of association study among sarcoidosis patients and controls

  Gene variant            Genotype   Patients (*n* = 86)   Controls (*n* = 50)   OR (95% CI)             *P*-value[\*](#tf3-1){ref-type="table-fn"}
  ----------------------- ---------- --------------------- --------------------- ----------------------- --------------------------------------------
  *VDR* rs2228570         CC         39                    23                    0.922 (0.428--1.987)    0.837
  CT                      34         25                                                                  
  TT                      13         2                                                                   
  *CC* vs. *CT + TT*                                                                                     
   *CYP27B1* rs10877012   CC         6                     14                    0.116 (0.034--0.394)    0.001
  CA                      39         19                                                                  
  AA                      41         17                                                                  
  *CC* vs. *CA + AA*                                                                                     
  * DBP* rs7041           TT         18                    6                     1.763 (0.597--5.204)    0.304
  TG                      39         29                                                                  
  GG                      29         15                                                                  
  *TT* vs. *TG + GG*                                                                                     
  * DBP* rs4588           CC         42                    25                    8.856 (1.006--77.953)   0.049
  CA                      34         24                                                                  
  AA                      10         1                                                                   
  *AA* vs. *CA + CC*                                                                                     
  * CYP2R1* rs10741657    GG         34                    28                    0.542 (0.251--1.170)    0.119
  GA                      42         18                                                                  
  AA                      10         4                                                                   
  *GG* vs. *GA + AA*                                                                                     

Logistic regression; p-value corrected for age.

![Distribution of CC vs. CA + AA genotypes of *CYP27B1* rs10877012 among sarcoidosis patients and controls](AMS-15-34153-g001){#f0001}

![Distribution of AA vs. CA + CC genotypes of *DBP* rs4588 among sarcoidosis patients and controls](AMS-15-34153-g002){#f0002}

Genotypes and serum 25(OH)D levels {#sec3.3}
----------------------------------

Median serum level of vitamin D in our cohort of sarcoidosis patients was 10.8 mg/l, where 44% of patients had a severe deficiency (a serum level of vitamin 25(OH)D \< 10 mg/l) ([Table II](#t0002){ref-type="table"}). We next wanted to establish the correlation between certain genotypes and serum vitamin D level in sarcoidosis patients. We found that patients carrying the CA plus AA genotypes of *DBP* rs4588 had a lower median level of serum 25(OH)D (9.8 mg/l) compared to carriers of the CC genotype (12.3 mg/l) ([Table IV](#t0004){ref-type="table"}). This difference was statistically significant (*p* = 0.046) ([Table V](#t0005){ref-type="table"}, [Figure 3](#f0003){ref-type="fig"}). Moreover, carriers of AA genotype showed the lowest median levels of vitamin D of 5.7 mg/l ([Table IV](#t0004){ref-type="table"}), which implies that allele A is a predisposing factor for a low vitamin D level.

###### 

Level of vitamin D depending on genotypes in sarcoidosis patients

  Genotype               Serum vitamin 25(OH)D level                        
  ---------------------- ----------------------------- ------ ------ ------ ----
  *VDR* rs2228570        TT                            9.3    5.5    11.8   13
  CT                     11.1                          8.2    17.0   34     
  CC                     11.6                          6.3    25.2   39     
  *CYP27B1* rs10877012   CC                            9.2    5.1    16.5   6
  CA                     10.8                          8.0    18.0   39     
  AA                     11.2                          5.9    17.6   41     
  *DBP* rs7041           TT                            9.8    4.0    20.7   18
  TG                     10.0                          5.8    15.9   39     
  GG                     12.8                          8.5    21.3   29     
  *DBP* rs4588           AA                            5.7    4.0    16.0   10
  CA                     10.0                          5.8    15.6   34     
  CC                     12.3                          8.0    21.6   42     
  *CYP2R1* rs10741657    GG                            10.6   7.0    17.0   34
  GA                     11.2                          5.9    18.0   42     
  AA                     10.9                          6.3    18.0   10     

###### 

Correlation of genotypes and level of vitamin D in sarcoidosis patients

  Genotype       25(OH)D levels \[mg/l\]   *P*-value[^a^](#tf5-1){ref-type="table-fn"}                 
  -------------- ------------------------- --------------------------------------------- ------ ------ -------
  *VDR*          CC + CT                   11.5                                          7.0    20.7   0.110
  TT             9.3                       5.5                                           11.8          
  *CYP27B1*      CA + CC                   10.8                                          8.0    18.0   0.869
  AA             11.2                      5.9                                           17.6          
  *DBP* rs7041   TT + TG                   10.0                                          5.5    16.0   0.131
  GG             12.8                      8.5                                           21.3          
  *DBP* rs4588   CA + AA                   9.8                                           5.1    15.8   0.046
  CC             12.3                      8.0                                           21.6          
  *CYP2R1*       GG + GA                   10.8                                          6.6    17.8   0.803
  AA             10.9                      6.3                                           18.0          

Median, first, and third quartile values of serum D3 levels in recessive genetic model of studied genes.

Mann-Whitney U test.

![Comparison of 25(OH)D levels between carriers of CC vs. CA + AA genotypes of *DBP* rs4588. The line inside the box represents the median value, and the box represents the first and third quartile of data](AMS-15-34153-g003){#f0003}

Discussion {#sec4}
==========

Sarcoidosis is probably caused by the influence of specific environmental factors on the immune system of genetically predisposed individuals \[[@cit0023]\]. This study examined the associations between SNPs of the genes encoding key players in the vitamin D metabolic pathway and sarcoidosis, and explored their relationship to vitamin D levels in sarcoidosis patients. Although the association between vitamin D and sarcoidosis, as well as other pulmonary diseases, has been studied for decades, this is one of the first studies designed to explore the role of polymorphisms in genes *CYP2R1*, *CYP27B1*, *DBP*, and *VDR* of the vitamin D metabolic pathway in sarcoidosis patients. This was a relatively large study, considering that the incidence of sarcoidosis in Serbia (population \~7 million) is 16--20 per 100,000 people \[[@cit0024]\], and is similar to that of countries at a similar latitude and skin color \[[@cit0002]\]. The main limitation of this study is the fact that sarcoidosis patients were older than the controls, and this difference was statistically significant. For that reason, all statistical calculations included adjustment for age.

Vitamin D 1α-hydroxylase is the product of the *CYP27B1* gene, and this product catalyzes the synthesis of 1,25(OH)~2~D, which is the active form of vitamin D which binds to the vitamin D receptor (VDR). There are some contradictory data \[[@cit0025], [@cit0026]\] available on the role of the *CYP27B1-1260* promoter polymorphism rs10877012 which was studied in this paper. While Lange *et al.* suggested that this polymorphism could influence serum concentrations of 1,25(OH)~2~D, Kitanaka *et al.* were unable to confirm this relationship in Japanese children \[[@cit0025], [@cit0026]\]. In our study, the carriers of CA and AA genotypes of this gene were associated with 9 times higher odds of suffering from sarcoidosis. The dominant CC genotype had a protective effect, lowering the odds for sarcoidosis significantly. In sarcoidosis it is believed that the macrophages convert 25(OH)D to 1,25(OH)~2~D, thus decreasing the vitamin D serum levels, with the product of this gene playing a key role \[[@cit0027], [@cit0028]\]. Since our results showed no significant association between the *CYP27B1* gene and 25(OH)D levels in sarcoidosis patients, we believe that increased expression, rather than polymorphisms, could be a mechanism relevant for this phenomenon.

The vitamin D receptor, which binds 1,25(OH)~2~D and forms a heterodimer with the retinoid X receptor and is crucial for vitamin D biological actions, is encoded by the *VDR* gene. In our study, we did not find that *VDR* rs2228570 is a susceptibility factor for sarcoidosis. We found that patients carrying the recessive TT genotype were more likely to have the lowest vitamin D levels, although this difference was not statistically significant ([Table III](#t0003){ref-type="table"}). Other authors have reported minor alleles of the *VDR* gene to alter VDR function and expression, and individuals with *VDR* minor genotypes were more sensitive to vitamin D administration and exhibited low calcium absorption \[[@cit0029]--[@cit0032]\]. Recent genome-wide association studies (GWAS) underline the contribution of vitamin D-related polymorphisms to variations in serum 25(OH)D levels \[[@cit0033], [@cit0034]\].

The vitamin D binding protein (DBP) is a serum α2-globulin which was initially named the "group-specific component" (Gc) in 1959 \[[@cit0035]\], and its functions include the transport of vitamin D and its metabolites, macrophage activation, actin scavenging, and fatty acid binding \[[@cit0036]\]. This protein has a half-life of less than 3 days, which is shorter compared to the half-life of 25(OH)D of several weeks, suggesting that the protein and its ligand are independently regulated \[[@cit0037]--[@cit0039]\]. DBP has a particularly high affinity to 25(OH)D, which leaves less than 1% of it circulating free \[[@cit0040], [@cit0041]\]. In our study, *DBP* rs4588 recessive genotype AA was shown to be a susceptibility factor for sarcoidosis. In addition, rs4588 was associated with 25(OH)D levels, with the recessive CC variant carriers having higher serum 25(OH)D levels than carriers of the CA and AA genotypes, thus confirming the results of previous studies \[[@cit0018]\]. We also found that carriers of AA genotype of *DBP* rs4588 have the lowest levels of 25(OH)D in sarcoidosis patients.

*CYP2R1* is known to encode the 25-hydroxylating cytochrome P-450 enzymes, and has been associated with variations in serum 25(OH)D levels \[[@cit0033], [@cit0042]--[@cit0045]\]. Nevertheless, in our study, it was not significantly associated with suffering from sarcoidosis, or with serum vitamin D levels in sarcoidosis patients.

Studying the interplay between sarcoidosis, vitamin D levels in the serum, and vitamin D pathway genes can provide valuable input for the understanding, as well as prevention and treatment, of this disease. Our results have underlined important associations between suffering from sarcoidosis and *CYP27B1* rs10877012 and *DBP* rs4588 SNPs, as well as serum vitamin D levels and *DBP* rs4588 SNPs, which might represent important aspects to consider in monitoring, measurement, and substitution in the treatment of patients with sarcoidosis in the future. In studies of the efficacy of vitamin D supplementation in the general population, *DBP* and *CYP2R1* genes, which were associated with baseline 25(OH)D levels, did not modify the response to supplementation \[[@cit0046]\]. Contrarily, two other SNPs (*CYP24A1* and *VDR*), which were not associated with baseline levels, did alter the response \[[@cit0046]\]. Fu *et al.* found that different *DBP* genotypes in healthy subjects may elicit different responses to the same vitamin D dose, although without proposing a specific genetic association model \[[@cit0047]\]. Despite the clear clinical benefits and effective reduction of the symptoms due to vitamin D supplementation among different immunological conditions \[[@cit0048]--[@cit0050]\], treatment of sarcoidosis patients in this respect is not so clear. In sarcoidosis patients this problem is even more complicated due to calcium disorders, allowing supplementation and sunlight exposure only for patients with normal levels of serum or urine calcium \[[@cit0024]\]. Future studies of sarcoidosis and other vitamin D associated diseases should focus their effort on better explaining these associations and exploring the influence of other factors related to vitamin D related SNPs on the prevention, outcomes, and response to therapy.

In conclusion, there is enough evidence to support the essential role of vitamin D and its metabolic pathway genes in sarcoidosis. This study has underlined the *CYP27B1* and *DBP* SNPs which were significantly associated with this disease and serum 25(OH)D levels in sarcoidosis patients for the first time. This study has improved our understanding of the role of genetic modifiers in the management of sarcoidosis, but its findings should be confirmed using a larger sample size in future studies.
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